Spotlight On... WuXi and PRA canceling joint venture in China; Recipharm to manufacture LIDDS drug; Perrigo adds Retin-A portfolio; and more...

With WuXi PharmaTech concentrating on manufacturing and PRA Health Sciences ($PRAH) developing its own global strategy, the two companies have decided to split up their China-focused joint venture. Instead, they will have an alliance but will divide their operations in the country after more than two years of collaboration. Story

> Sweden's Recipharm will invest SEK 5 million in LIDDS as part of an agreement for the contract manufacturer to scale up for commercial production of LIDDS treatment candidate for prostate cancer. Release

> Perrigo ($PRGO) has reacquired a portfolio of generic Retin-A (tretinoin) products from Matawan Pharmaceuticals. Release

> Pharma's price-gouging poster boy Martin Shkreli was arrested by the FBI Thursday. Story

 

Suggested Articles

President Trump is set to issue an executive order centering on U.S. production for drugs and medical supplies, and pharma is sure to push back. 

The lawmakers question Kodak's fitness for such a major pharma manufacturing deal, as well as suspicious stock transactions by company leadership.

AZ's China COVID-19 vaccine deal comes after supply agreements with the U.S., the U.K., EU and Brazil, as well as licensing pacts in India and Japan.